natl health inv - NHI
NHI
Close Chg Chg %
70.15 0.13 0.19%
Closed Market
70.28
+0.13 (0.19%)
Volume: 370.88K
Last Updated:
Sep 10, 2026, 3:59 PM EDT
Company Overview: natl health inv - NHI
NHI Key Data
| Open $70.69 | Day Range 69.95 - 71.06 |
| 52 Week Range 67.95 - 91.38 | Market Cap $3.51B |
| Shares Outstanding 49.11M | Public Float 47.94M |
| Beta 0.55 | Rev. Per Employee N/A |
| P/E Ratio 20.67 | EPS $3.47 |
| Yield 524.29% | Dividend $0.94 |
| EX-DIVIDEND DATE Sep 30, 2026 | SHORT INTEREST N/A |
| AVERAGE VOLUME 340.49K |
NHI Performance
| 1 Week | -0.95% | ||
| 1 Month | -3.76% | ||
| 3 Months | -2.62% | ||
| 1 Year | -10.32% | ||
| 5 Years | 20.22% |
NHI Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
9
Full Ratings ➔
An error occurred while fetching the data.
An error occurred while fetching the data.
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 81.875 | |
| Number of Ratings | 9 | Current Quarters Estimate | 1.19 | |
| FY Report Date | 09 / 2026 | Current Year's Estimate | 3.85 | |
| Last Quarter’s Earnings | 1.15 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 3.02 | Next Fiscal Year Estimate | 3.125 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 5 | 5 | 5 | 6 |
| Mean Estimate | 1.19 | 0.75 | 3.85 | 3.12 |
| High Estimates | 1.96 | 0.82 | 4.68 | 3.45 |
| Low Estimate | 0.66 | 0.67 | 3.30 | 2.85 |
| Coefficient of Variance | 57.59 | 7.66 | 17.03 | 6.63 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 6 | 5 | 5 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 3 | 3 | 3 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Natl Health Inv - NHI
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Natl Health Inv - NHI
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 31, 2026 | Kevin C. Pascoe Chief Investment Officer | 73,082 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 31, 2026 | John L. Spaid CFO/EVP Finance | 56,601 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 20, 2026 | D. Eric Mendelsohn CEO and President; Director | 137,505 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $73.34 per share | 10,084,616.70 |
| Feb 20, 2026 | D. Eric Mendelsohn CEO and President; Director | 115,450 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $91.02 per share | 10,508,259.00 |
| Feb 20, 2026 | D. Eric Mendelsohn CEO and President; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | James R. Jobe Director | 41,555 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $73.34 per share | 3,047,643.70 |
| Feb 20, 2026 | James R. Jobe Director | 33,497 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $91.02 per share | 3,048,896.94 |
| Feb 20, 2026 | James R. Jobe Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |